DGAP-News
SYGNIS AG: SYGNIS AG receives binding commitment for the purchase of shares for up to EUR 3.5 million within the scope of the ongoing capital increases to finance the acquisition of Innova Biosciences Ltd.
DGAP-News: SYGNIS AG / Key word(s): Agreement
Press Release |
Madrid, Spain, and Heidelberg, Germany, 25 May, 2017 - SYGNIS AG (Frankfurt: LIO1; ISIN: DE000A1RFM03; Prime Standard) today received a binding commitment for the purchase of shares
up to a total of EUR 3.5 million as part of the previously announced cash capital increases to finance the acquisition of Innova Biosciences Ltd. Under the terms of the agreement signed today, the
investor has committed to purchase up to 2,536,000 new shares at a price of EUR 1.38 per new share. The obligation is subject to the condition that the DAX closing price
on the settlement day is not more than 10% lower than the DAX closing price as of today.
"We are delighted by the positive feedback on the planned acquisition of Innova Biosciences Ltd. and the great support we experience from investors for this important strategic transaction,"
Pilar de la Huerta, Co-CEO and CBDO of SYGNIS, said.
For further information on this transaction please also visit http://capital.sygnis.com.
For further information, please contact:
SYGNIS AG
Dr. Heikki Lanckriet
Co-CEO/CSO
Phone : +44 1223 873 364
Email: heikki.lanckriet@sygnis.com
Pilar de la Huerta
Co-CEO/CBDO
Phone: +34 91 192 36 50
Email: pdelahuerta@sygnis.com